Equibles does not estimate personal net worth.
Get an email with a short summary when Harmony Biosciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get HRMY alertsGlenn Reicin is recorded as CFO at Harmony Biosciences Holdings, Inc. (HRMY) since April 14, 2026. Harmony Biosciences Holdings, Inc. reported in an 8-K filed July 16, 2026 that Glenn Reicin resigned as Chief Financial Officer, effective July 16, 2026. Harmony Biosciences Holdings, Inc. reported in an 8-K filed April 14, 2026 that Glenn Reicin was appointed Chief Financial Officer, effective April 14, 2026. Glenn Reicin has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Harmony Biosciences Holdings, Inc. on June 9, 2026. Harmony Biosciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Harmony Biosciences Holdings, Inc. includes Jeffrey Dayno (CEO), Jeffrey M. Dayno (CEO and Board Member), Peter Anastasiou (CEO, COO and Board Member) and 7 others.
“On July 16, 2026, the Company announced that Glenn Reicin, the Company's Chief Financial Officer, will be stepping down as the Company's Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.”
“On April 14, 2026, the Company announced that Glenn Reicin has been appointed as Chief Financial Officer of the Company, effective as of April 14, 2026.”
“With respect to figuring out indications on the orexins, I think what you're going to see is a process. You see a pretty broad effort on Phase II, and then we'll have the data dictate, but the selection of the targets will really be determined by our strengths, right?”
“I'm delighted to join this organization and help contribute to the growth and significant value creation. And I should mention that I was drawn to Harmony by the strength of its commercial foundation and self-funding financial model that positions us to build and grow from a place of strength.”
2026-04-14–present
2026-04-14–2026-07-16
Biotechnology · Healthcare
CFO
2026-04-14–present
